U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s Duchenne muscular dystrophy…
Endocyte kicked off the week with an incredible gain, making it one of the best, if not the best, performing stocks in Monday’s session.
Rigel Pharmaceuticals has suffered over the past year, but it seems this update may be the catalyst it has been looking for.
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of Dravet syndrome.
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial.
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Axovant Sciences shares cratered early on Tuesday after the firm provided an update from its late-stage Alzheimer’s trial.
Versartis shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in pediatric growth hormone deficiency.
As we have said before, updates from the FDA have the potential to make or break a company. In this case it seems like a mild setback, but further complications could prove to be…
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
